Mumbai: With the US Pharma Pfizer’s COVID-19 vaccine showing 95 percent efficacy in their late-stage trials, they may begin delivery of the vaccination before December this year.
The pharma company is now fully prepared to seek emergency US and European authorization for its COVID-19 vaccine.
If I had to guess we could get approval in the second half of December and start delivery before Christmas, but only when all move forward positively, “Chief Executive of BioNTech (German partner of Pfizer) Officer Yugur Sahin told Reuters TV.
The partners are expecting approval from the US Food and Drug Administration by mid-December of this year, and conditional approval in the European Union in the second half of the same month.
Pfizer’s vaccine was found to be 90 percent effective last week. However, last-stage testing showed that yesterday’s findings showed it was 95 percent effective.
The companies said in a joint statement that there were no serious side effects in 41,135 adults who received two doses. The most common reactions were that 3.7 percent of the participants experienced fatigue and 2 percent had a headache.
Pfizer said the study is with 170 confirmed cases of COVID-19, in which 95 percent efficacy was demonstrated 28 days after the first dose of the vaccine candidate BNT162b2.
Within days, we plan to submit a request to the US FDA for the USA based on the totality of the safety and efficacy data collected, as well as the creation of data related to the quality and consistency of the vaccine candidate.
(With Reuters Inputs)